Pneumovax 23 Market Report 2026
Download Free Sample Buy Now
Pneumovax 23 Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Pneumovax 23 Market Report 2026

Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Pneumovax 23 Market Overview

• The Pneumovax 23 market growth in the historic period has been driven by expansion of national immunization guidelines, rising incidence of pneumococcal infections in elderly populations

• Market expansion is supported by increasing investments in adult vaccination programs, rising focus on infectious disease prevention

• Growth Driver: Rising Global Incidence Of Pneumococcal Diseases To Drive Demand For Pneumovax 23 Vaccine

• North America was the largest region in 2025.

What Is Covered Under Pneumovax 23 Market?

Pneumovax 23 is a vaccine that protects against 23 types of pneumococcal bacteria, which can cause serious illnesses such as pneumonia, meningitis, and bloodstream infections. It is primarily used for older adults and individuals with certain medical conditions to prevent invasive pneumococcal diseases. The vaccine stimulates the immune system to recognize and fight these specific strains of bacteria, providing long-term protection.

The main formulations of pneumovax 23 are pneumococcal polysaccharide vaccine (PPV), and pneumococcal conjugate vaccine (PCV). Pneumococcal polysaccharide vaccine (PPV) is a vaccine designed to protect against multiple strains of pneumococcal bacteria using polysaccharides from bacterial capsules. Pneumovax 23 is a widely used pneumococcal polysaccharide vaccine that protects against 23 strains of pneumococcal bacteria. For clinical indications such as pneumococcal disease prevention and utilized by end users such as hospitals, clinics, ambulatory surgical centers, and pharmacies.

Pneumovax 23 Market Global Report 2026 Market Report bar graph

What Is The Pneumovax 23 Market Size and Share 2026?

The growth in the historic period can be attributed to expansion of national immunization guidelines, rising incidence of pneumococcal infections in elderly populations, availability of polysaccharide vaccines, growth in preventive healthcare initiatives, increased vaccination awareness.

What Is The Pneumovax 23 Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in adult vaccination programs, rising focus on infectious disease prevention, expansion of pharmacy-based immunization services, growing demand for long-term vaccine protection, advancements in vaccine storage and distribution. Major trends in the forecast period include increasing focus on adult and geriatric immunization programs, rising demand for pneumococcal disease prevention, growing adoption of preventive vaccination strategies, expansion of public health immunization campaigns, enhanced cold-chain vaccine management.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Pneumovax 23 Market Segmentation

1) By Formulation: Pneumococcal Polysaccharide Vaccine (PPV), Pneumococcal Conjugate Vaccine (PCV)

2) By Clinical Indication: Pneumococcal Disease Prevention

3) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies

What Are The Drivers Of The Pneumovax 23 Market?

The increasing incidence of pneumococcal diseases is expected to propel the growth of the pneumovax 23 market going forward. Pneumococcal diseases are infections caused by the bacterium streptococcus pneumoniae, commonly known as pneumococcus, which can lead to various health issues, from mild conditions such as sinusitis and otitis media to severe illnesses such as pneumonia and meningitis, potentially requiring hospitalization. The increasing incidence of pneumococcal diseases can be attributed to factors such as reduced vaccination coverage during the COVID-19 pandemic, heightened risk among individuals with chronic health conditions, and the resurgence of respiratory infections following the easing of social restrictions. Pneumovax 23 prevents pneumococcal diseases by immunizing against 23 strains of streptococcus pneumoniae, reducing the risk of infections such as pneumonia, meningitis, and bacteremia. For instance, in June 2025, according to the Office for Health Improvement and Disparities, a UK-based government body focused on public health and reducing health inequalities, in the financial year ending 2024, emergency hospital admissions for pneumonia in England rose by 16% compared to the prior year, reaching a rate of 430 per 100,000 people and accounting for approximately 252,912 admissions. Therefore, the increasing incidence of pneumococcal diseases globally is driving the growth of the pneumovax 23 industry.

The increasing rate of urbanization is anticipated to drive the growth of the pneumovax 23 market in the future. Growing urbanization is driven by factors such as industrialization, which creates improved employment opportunities in cities, better access to education and healthcare, and the overall allure of urban lifestyles that attract individuals from rural areas seeking a higher standard of living. Urban populations typically have greater access to health education and awareness campaigns. This can lead to higher vaccination rates as people recognize the importance of preventing pneumococcal diseases. For instance, in April 2023, according to a report published by the World Bank Group, a US-based financial institution, about 56% of the world's population, or 4.4 billion people, live in urban areas, a trend projected to continue with the urban population expected to nearly double by 2050, reaching nearly 70%. Additionally, urban land consumption exceeds population growth by up to 50%, adding an estimated 1.2 million square kilometers of new urban area by 2030. Therefore, the rise in urbanization is driving the growth of the pneumovax 23 industry.

The expansion of government immunization initiatives is expected to propel the growth of the pneumovax 23 market going forward. Government immunization initiatives are organized by national or local governments to promote and provide vaccines to populations to prevent vaccine-preventable diseases, increase vaccination coverage, and improve public health outcomes through programs that may include routine immunization schedules, vaccination campaigns, and public awareness efforts. Expanding government immunization initiatives are driven by the need to improve public health outcomes, increase vaccination coverage, and address gaps in immunization that have emerged due to factors such as the COVID-19 pandemic, ensuring equitable access to vaccines for all populations to prevent the spread of infectious diseases. Government immunization initiatives boost Pneumovax 23 by increasing access to the vaccine, promoting public awareness, and driving higher vaccination rates to prevent pneumococcal diseases. For instance, in July 2024, according to the Gavi, a Switzerland-based vaccine alliance, reported that in 2023, about 69 million children received Gavi-supported routine immunizations, close to the highest annual totals ever. By 2024, over 72 million children in lower-income countries were vaccinated with Gavi support, showing continued scale-up. Therefore, expanding government immunization initiatives is driving the growth of the pneumovax 23 industry.

Key Players In The Global Pneumovax 23 Market

Major companies operating in the pneumovax 23 market are Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

Need data on a specific region in this market?
Request Regional Data

Regional Insights

North America was the largest region in the pneumovax 23 market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Pneumovax 23 Market?

The pneumovax 23 market consists of the sales of pneumovax 23 vaccine (the primary 23-valent pneumococcal polysaccharide vaccine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pneumovax 23 Market Report 2026?

The pneumovax 23 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pneumovax 23 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Pneumovax 23 Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $ billion
Revenue Forecast In 2035 $ billion
Growth Rate No CAGR found from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Formulation, Clinical Indication, End User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Pneumovax 23 Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Pneumovax 23 Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Pneumovax 23 Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Pneumovax 23 Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics And Precision Medicine

4.1.2 Sustainability, Climate Tech And Circular Economy

4.1.3 Industry 4.0 And Intelligent Manufacturing

4.1.4 Digitalization, Cloud, Big Data And Cybersecurity

4.1.5 Internet Of Things (Iot), Smart Infrastructure And Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Focus On Adult And Geriatric Immunization Programs

4.2.2 Rising Demand For Pneumococcal Disease Prevention

4.2.3 Growing Adoption Of Preventive Vaccination Strategies

4.2.4 Expansion Of Public Health Immunization Campaigns

4.2.5 Enhanced Cold-Chain Vaccine Management

5. Pneumovax 23 Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Clinics

5.3 Pharmacies

5.4 Ambulatory Care Centers

5.5 Public Health Organizations

6. Pneumovax 23 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Pneumovax 23 Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Pneumovax 23 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Pneumovax 23 Market Size, Comparisons And Growth Rate Analysis

7.3. Global Pneumovax 23 Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Pneumovax 23 Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Pneumovax 23 Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Pneumovax 23 Market Segmentation

9.1. Global Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Pneumococcal Polysaccharide Vaccine (PPV), Pneumococcal Conjugate Vaccine (PCV)

9.2. Global Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Pneumococcal Disease Prevention

9.3. Global Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies

10. Pneumovax 23 Market Regional And Country Analysis

10.1. Global Pneumovax 23 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Pneumovax 23 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Pneumovax 23 Market

11.1. Asia-Pacific Pneumovax 23 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Pneumovax 23 Market

12.1. China Pneumovax 23 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Pneumovax 23 Market

13.1. India Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Pneumovax 23 Market

14.1. Japan Pneumovax 23 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Pneumovax 23 Market

15.1. Australia Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Pneumovax 23 Market

16.1. South Korea Pneumovax 23 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

16.2. South Korea Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Pneumovax 23 Market

17.1. Western Europe Pneumovax 23 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. Western Europe Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Pneumovax 23 Market

18.1. UK Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Pneumovax 23 Market

19.1. Germany Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Pneumovax 23 Market

20.1. France Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Pneumovax 23 Market

21.1. Eastern Europe Pneumovax 23 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

21.2. Eastern Europe Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Pneumovax 23 Market

22.1. North America Pneumovax 23 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

22.2. North America Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Pneumovax 23 Market

23.1. USA Pneumovax 23 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

23.2. USA Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Pneumovax 23 Market

24.1. Canada Pneumovax 23 Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

24.2. Canada Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Pneumovax 23 Market

25.1. South America Pneumovax 23 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

25.2. South America Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Pneumovax 23 Market

26.1. Middle East Pneumovax 23 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Middle East Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Pneumovax 23 Market

27.1. Africa Pneumovax 23 Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

27.2. Africa Pneumovax 23 Market, Segmentation By Formulation, Segmentation By Clinical Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Pneumovax 23 Market Regulatory and Investment Landscape

29. Pneumovax 23 Market Competitive Landscape And Company Profiles

29.1. Pneumovax 23 Market Competitive Landscape And Market Share 2024

29.1.1. Top 10 Companies (Ranked by revenue/share)

29.2. Pneumovax 23 Market - Company Scoring Matrix

29.2.1. Market Revenues

29.2.2. Product Innovation Score

29.2.3. Brand Recognition

29.3. Pneumovax 23 Market Company Profiles

29.3.1. Merck & Co. Inc. (Merck Sharp & Dohme Corp.) Overview, Products and Services, Strategy and Financial Analysis

30. Global Pneumovax 23 Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Pneumovax 23 Market

32. Pneumovax 23 Market High Potential Countries, Segments and Strategies

32.1 Pneumovax 23 Market In 2030 - Countries Offering Most New Opportunities

32.2 Pneumovax 23 Market In 2030 - Segments Offering Most New Opportunities

32.3 Pneumovax 23 Market In 2030 - Growth Strategies

32.3.1 Market Trend Based Strategies

32.3.2 Competitor Strategies

33. Appendix

33.1. Abbreviations

33.2. Currencies

33.3. Historic And Forecast Inflation Rates

33.4. Research Inquiries

33.5. The Business Research Company

33.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Pneumovax 23 Market, Overview Of Key Products - Product Examples
  • Table 2: Global Pneumovax 23 Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Pneumovax 23 Market, Supply Chain Analysis
  • Table 4: Global Pneumovax 23 Market, Major Raw Material Providers
  • Table 5: Global Pneumovax 23 Market, Major Resource Providers
  • Table 6: Global Pneumovax 23 Market, Major Manufacturers (Suppliers)
  • Table 7: Global Pneumovax 23 Market, Major Distributors And Channel Partners
  • Table 8: Global Pneumovax 23 Market, Key Technologies & Future Trends
  • Table 9: Global Pneumovax 23 Market, Major Trends
  • Table 10: Global Pneumovax 23 Market, Major End Users
  • Table 11: Global Pneumovax 23 Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Pneumovax 23 Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Pneumovax 23 Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Pneumovax 23 Market - TAM, US$ Billion, 2025
  • Table 15: Global Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Pneumovax 23 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Pneumovax 23 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Asia-Pacific, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Asia-Pacific, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Asia-Pacific, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: China, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: China, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: China, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: India, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: India, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: India, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: Japan, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: Japan, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: Japan, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: Australia, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Australia, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Australia, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: South Korea, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: South Korea, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: South Korea, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Western Europe, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Western Europe, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Western Europe, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: UK, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: UK, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: UK, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: Germany, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Germany, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Germany, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: France, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: France, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: France, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: Eastern Europe, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Eastern Europe, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Eastern Europe, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: North America, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: North America, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: North America, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: USA, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: USA, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: USA, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Canada, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Canada, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Canada, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: South America, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: South America, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: South America, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Middle East, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Middle East, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Middle East, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Africa, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Africa, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Africa, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Global Pneumovax 23 Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 72: Global Pneumovax 23 Market - Company Scoring Matrix
  • Table 73: Merck & Co. Inc. (Merck Sharp & Dohme Corp.) Financial Performance
  • Table 74: Global Pneumovax 23 Market, Competitive Benchmarking (In USD Billions)
  • Table 75: Global Pneumovax 23 Market, Competitive Dashboard
  • Table 76: Global Pneumovax 23 Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 77: Global, Pneumovax 23 Market Size Gain ($ Billion), Segmentation By Formulation, 2025 – 2030
  • Table 78: Global, Pneumovax 23 Market Size Gain ($ Billion), Segmentation By Clinical Indication, 2025 – 2030
  • Table 79: Global, Pneumovax 23 Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

List Of Figures

    Figure 1: Global Pneumovax 23 Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Pneumovax 23 Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Pneumovax 23 Market, Supply Chain Analysis
  • Figure 4: Global Pneumovax 23 Market, Major Raw Material Providers
  • Figure 5: Global Pneumovax 23 Market, Major Resource Providers
  • Figure 6: Global Pneumovax 23 Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Pneumovax 23 Market, Major Distributors And Channel Partners
  • Figure 8: Global Pneumovax 23 Market, Key Technologies & Future Trends
  • Figure 9: Global Pneumovax 23 Market, Major Trends
  • Figure 10: Global Pneumovax 23 Market, Major End Users
  • Figure 11: Global Pneumovax 23 Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Pneumovax 23 Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Pneumovax 23 Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Pneumovax 23 Market - TAM, US$ Billion, 2025
  • Figure 15: Global Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Pneumovax 23 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Pneumovax 23 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Asia-Pacific, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Asia-Pacific, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Asia-Pacific, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: China, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: China, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: China, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: India, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: India, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: India, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: Japan, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: Japan, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: Japan, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: Australia, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Australia, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Australia, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: South Korea, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: South Korea, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: South Korea, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Western Europe, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Western Europe, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Western Europe, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: UK, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: UK, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: UK, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: Germany, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Germany, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Germany, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: France, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: France, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: France, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: Eastern Europe, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Eastern Europe, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Eastern Europe, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: North America, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: North America, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: North America, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: USA, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: USA, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: USA, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Canada, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Canada, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Canada, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: South America, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: South America, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: South America, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Middle East, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Middle East, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Middle East, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Africa, Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Africa, Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Africa, Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Global Pneumovax 23 Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 72: Global Pneumovax 23 Market - Company Scoring Matrix
  • Figure 73: Merck & Co. Inc. (Merck Sharp & Dohme Corp.) Financial Performance
  • Figure 74: Global Pneumovax 23 Market, Competitive Benchmarking (In USD Billions)
  • Figure 75: Global Pneumovax 23 Market, Competitive Dashboard
  • Figure 76: Global Pneumovax 23 Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 77: Global, Pneumovax 23 Market Size Gain ($ Billion), Segmentation By Formulation, 2025 – 2030
  • Figure 78: Global, Pneumovax 23 Market Size Gain ($ Billion), Segmentation By Clinical Indication, 2025 – 2030
  • Figure 79: Global, Pneumovax 23 Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Read More About Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

Read More About Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Read More About Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Read More About CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Read More About Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Read More About Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Commercial P2P CDN Market Report 2026 - Global Outlook – By Component (Solution, Services), By Type (Video, Non-Video), By End-User (BFSI, Retail And E-Commerce, Manufacturing, Government And Defense, Energy And Utilitie...

Polybutylene Terephthalate (PBT) Market Report 2026 - Global Outlook – By Type (Reinforced Polybutylene Terephthalate, Unreinforced Polybutylene Terephthalate ), By Processing Method (Injection Molding, Extrusion, Blow M...

Biopreservation Market Report 2026 - Global Outlook – By Type (Biopreservation Equipment, Biopreservation Media), By Biospecimen (Human Tissue Samples, Organs, Stem Cells, Other Biospecimens), By Application (Therapeutic...

Semiconductor Capital Equipment Market Report 2026 - Global Outlook – By Type (Wafer Manufacturing Equipment, Assembly And Packaging Equipment, Test Equipment, Other Types), By Application (Wafer Processing, Surface Cond...

Marketing Technology Market Report 2026 - Global Outlook – By Product (Social Media Tools, Content Marketing Tools, Rich Media Tool, Automation Tool, Data And Analytics Tools, Sales Enablement Tools), By Deployment (On-P...

Commercial Display Market Report 2026 - Global Outlook – By Product ( Digital Signage, Display Monitor, Display Television (TV)), By Component ( Hardware, Software, Service), By Technology ( Liquid Crystal Display (LCD),...

Automotive Silicone Market Report 2026 - Global Outlook – By Type (Elastomers, Resins, Gels, Fluids), By Form (Sealant, Tape), By Application (Interior and Exterior, Engines, Electrical, Other Applications) – Market Size...

Polyisobutylene Market Report 2026 - Global Outlook – By Product (Conventional PIB, Highly Reactive PIB), By Molecular Weight (Low Molecular Weight, Medium Molecular Weight, High Molecular Weight), By Application (Tires ...

Frequently Asked Questions

The Pneumovax 23 market was valued at $ billion in 2025, increased to $ billion in 2026, and is projected to reach $ billion by 2030.

The global Pneumovax 23 market is expected to grow at a CAGR of nan% from 2026 to 2035 to reach $ billion by 2035.

Some Key Players in the Pneumovax 23 market Include, Merck & Co. Inc. (Merck Sharp & Dohme Corp.) .

Major trend in this market includes: nan. For further insights on this market. request a sample here

North America was the largest region in the pneumovax 23 market in 2025. The regions covered in the pneumovax 23 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us